Salīdzināt metodes
Apskatiet izvēlētās metodes blakus; rindas, kas atšķiras, ir izceltas.
| Mērķa izraisīta zāļu izplatība× | Populācijas farmakodinamiskā modelēšana× | |
|---|---|---|
| Nozare | Farmakoloģija | Farmakoloģija |
| Saime | Process / pipeline | Process / pipeline |
| Izcelsmes gads≠ | 2001 | 1992 |
| Autors≠ | Donald Mager and William Jusko | Lewis Sheiner and Stephen Roush |
| Tips≠ | nonlinear PK modeling | dose-response modeling |
| Pirmavots≠ | Mager, D. E., & Jusko, W. J. (2001). General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics, 28(6), 507-532. DOI ↗ | Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57. link ↗ |
| Citi nosaukumi≠ | TMDD, target-driven clearance | PopPD, population PD, hierarchical PD modeling |
| Saistītās | 3 | 3 |
| Kopsavilkums≠ | Target-mediated drug disposition (TMDD) is a mechanistic framework describing nonlinear pharmacokinetics arising from drug binding to a target receptor or protein. Developed by Mager and Jusko in 2001, TMDD explains saturable clearance, dose-dependent half-lives, and time-dependent changes in plasma concentrations observed with protein therapeutics and some small-molecule drugs. | Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction. |
| ScholarGateDatu kopa ↗ |
|
|